{
    "id": 28347,
    "fullName": "RET G810S",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "RET G810S lies within the protein kinase domain of the Ret protein (UniProt.org). G810S has been demonstrated to confer resistance to tyrosine kinase inhibitors in the context of KIF5B-RET in culture (PMID: 29908090), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5979,
        "geneSymbol": "RET",
        "terms": [
            "RET",
            "CDHF12",
            "CDHR16",
            "HSCR1",
            "MEN2A",
            "MEN2B",
            "MTC1",
            "PTC",
            "RET-ELE1"
        ]
    },
    "variant": "G810S",
    "createDate": "07/10/2018",
    "updateDate": "10/07/2019",
    "referenceTranscriptCoordinates": {
        "id": 176073,
        "transcript": "NM_020975",
        "gDna": "chr10:g.43119566G>A",
        "cDna": "c.2428G>A",
        "protein": "p.G810S",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14432,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET G810S in the context of KIF5B-RET were resistant to Caprelsa (vandetanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30011,
                "profileName": "KIF5B - RET RET G810S"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14433,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET G810S in the context of KIF5B-RET were resistant to Ofev (nintedanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30011,
                "profileName": "KIF5B - RET RET G810S"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14429,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET G810S in the context of KIF5B-RET were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30011,
                "profileName": "KIF5B - RET RET G810S"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14430,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET G810S in the context of KIF5B-RET were resistant to Lenvima (lenvatinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30011,
                "profileName": "KIF5B - RET RET G810S"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20205,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, acquired RET G810S was detected in multiple lesions from a patient with non-small cell lung cancer harboring KIF5B-RET who progressed after initial response to Selpercatinib (LOXO-292) treatment (PMID: 31988000).",
            "molecularProfile": {
                "id": 30011,
                "profileName": "KIF5B - RET RET G810S"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17728,
                    "pubMedId": 31988000,
                    "title": "RET Solvent Front Mutations Mediate Acquired\u00a0Resistance to Selective RET Inhibition in\u00a0RET-Driven Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31988000"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20204,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, acquired RET G810C and RET G810S mutations were detected in multiple lesions from a patient with non-small cell lung cancer harboring KIF5B-RET who progressed after initial response to Selpercatinib (LOXO-292) treatment (PMID: 31988000).",
            "molecularProfile": {
                "id": 34925,
                "profileName": "KIF5B - RET RET G810C RET G810S"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17728,
                    "pubMedId": 31988000,
                    "title": "RET Solvent Front Mutations Mediate Acquired\u00a0Resistance to Selective RET Inhibition in\u00a0RET-Driven Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31988000"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20215,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selpercatinib (LOXO-292) treatment resulted in initial tumor regression in colorectal cancer patient-derived xenograft (PDX) models harboring CCDC6-RET, however, tumors reemerged in 4 of 5 models, and 3 of 4 were found to have acquired RET G810S, one with a co-incident RET V804M mutation in trans (PMID: 31988000).",
            "molecularProfile": {
                "id": 34940,
                "profileName": "CCDC6 - RET RET G810S"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17728,
                    "pubMedId": 31988000,
                    "title": "RET Solvent Front Mutations Mediate Acquired\u00a0Resistance to Selective RET Inhibition in\u00a0RET-Driven Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31988000"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20219,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-small cell lung cancer harboring CCDC6-RET had an initial systemic and intracranial response to Selpercatinib (LOXO-292), however, demonstrated progression after 11 months of treatment and was found to have acquired RET G810S (PMID: 31988000).",
            "molecularProfile": {
                "id": 34940,
                "profileName": "CCDC6 - RET RET G810S"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17728,
                    "pubMedId": 31988000,
                    "title": "RET Solvent Front Mutations Mediate Acquired\u00a0Resistance to Selective RET Inhibition in\u00a0RET-Driven Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31988000"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20214,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selpercatinib (LOXO-292) treatment resulted in initial tumor regression in colorectal cancer patient-derived xenograft (PDX) models harboring CCDC6-RET, however, tumors reemerged in 4 of 5 models, and 3 of 4 were found to have acquired RET G810S, one with a co-incident RET V804M mutation in trans (PMID: 31988000).",
            "molecularProfile": {
                "id": 34941,
                "profileName": "CCDC6 - RET RET V804M RET G810S"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17728,
                    "pubMedId": 31988000,
                    "title": "RET Solvent Front Mutations Mediate Acquired\u00a0Resistance to Selective RET Inhibition in\u00a0RET-Driven Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31988000"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30003,
            "profileName": "RET G810S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30011,
            "profileName": "KIF5B - RET RET G810S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34925,
            "profileName": "KIF5B - RET RET G810C RET G810S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34940,
            "profileName": "CCDC6 - RET RET G810S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34941,
            "profileName": "CCDC6 - RET RET V804M RET G810S",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 176074,
            "transcript": "NM_020630",
            "gDna": "chr10:g.43119566G>A",
            "cDna": "c.2428G>A",
            "protein": "p.G810S",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 176073,
            "transcript": "NM_020975",
            "gDna": "chr10:g.43119566G>A",
            "cDna": "c.2428G>A",
            "protein": "p.G810S",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}